Core Viewpoint - The company, Jinfang Pharmaceutical-B (02595.HK), announced the board's resolution to propose the adoption of an H-share buyback plan and an H-share incentive plan on November 24, 2025 [1] Group 1 - The board of Jinfang Pharmaceutical-B has made a decision regarding the implementation of a buyback plan for H-shares [1] - An incentive plan for H-shares has also been proposed by the company [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容引致的任何損失承擔任何責任。 GenFleet Therapeutics (Shanghai) Inc. 股份計劃的宗旨 H股購股權計劃及H股股份激勵計劃（統稱「股份計劃」）旨在為合資格人士（包括 僱員參與者、服務提供者及關聯實體參與者）提供獲得本公司資本權益的機會， 並鼓勵合資格人士為本公司及本公司股東（「股東」）的整體利益，努力提升本公司 及其股份的價值。股份計劃預期將為本公司留任、激勵、回報合資格人士，向其 提供薪酬、酬金及/或福利提供靈活的方式。 計劃限額及服務提供者分項限額 根據H股購股權計劃將予授出的購股權所涉及的本公司H股（「H股」）將以(i)發行 及配發新H股；及/或(ii)轉讓本公司的庫存股份（如有）的方式滿足。根據H股股份 激勵計劃將予授出的股份獎勵相關的H股將由指定受託人透過以下方式取得：(i) 按面值認購本公司發行的新H股；(ii)按照本公司的指示及計劃規則的相關規定， 利用計劃資金按當時的市價通過二級市場收購； ...

（文章来源：每日经济新闻） 每经AI快讯，劲方医药-B(02595.HK)尾盘涨超8%，截至发稿，涨7.46%，报31.1港元，成交额2808.49万 港元。 ...

Core Viewpoint - Jinfang Pharmaceutical-B (02595) experienced a significant stock price increase, rising over 8% towards the end of trading, with a current price of 31.1 HKD and a trading volume of 28.08 million HKD [1] Group 1: Clinical Trial Announcement - On November 11, Jinfang Pharmaceutical announced the initiation of a Phase III clinical trial comparing the efficacy and safety/tolerability of GFH375 monotherapy versus investigator-selected chemotherapy for patients with KRAS G12D mutated metastatic pancreatic cancer [1] - The company’s prospectus indicates that GFH375 is being developed as a first-in-class oral G12D inhibitor, with plans for the monotherapy to enter Phase I/II trials by June 2024 [1] - GFH375/VS-7375 has received FDA Fast Track designation this year, allowing it to be used for first-line and subsequent treatment of locally advanced and metastatic KRAS G12D mutated PDAC patients [1] Group 2: Previous Data Presentation - Early data on GFH375 monotherapy for solid tumors was presented at prestigious international academic conferences such as ASCO and WCLC this year, through late-breaking abstracts and oral presentations [1]

Core Viewpoint - Jinfang Pharmaceutical-B (02595) experienced a significant stock price increase, rising over 8% towards the end of trading, with a current price of 31.1 HKD and a trading volume of 28.08 million HKD [1] Group 1: Clinical Trial Announcement - On November 11, Jinfang Pharmaceutical announced the initiation of a Phase III clinical trial comparing the efficacy and safety/tolerability of GFH375 monotherapy versus investigator-selected chemotherapy for patients with KRAS G12D mutated metastatic pancreatic cancer [1] - The company’s prospectus indicates that GFH375 is being developed as a first-line oral G12D inhibitor, with plans for the monotherapy to enter Phase I/II trials by June 2024 [1] - GFH375/VS-7375 has received FDA Fast Track designation this year, allowing it to be used for both first-line and subsequent treatments of locally advanced and metastatic KRAS G12D mutated PDAC patients [1] Group 2: Early Data Presentation - Early data on GFH375 monotherapy for solid tumors was presented at prestigious international academic conferences such as ASCO and WCLC this year, through late-breaking abstracts (LBA) and oral presentations [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 勁方醫藥科技 ( 上海 ) 股份有限公司 （於中華人民共和國註冊成立的股份有限公司, 「本公司」） 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02595 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 324,643,020 | RMB | | 0.1 RMB | | 32,464,302 | | 增加 / 減少 (-) | | | 13,386,000 | | | RMB | | 1,338,600 | | 本月底結存 | | | 338,029,020 | RMB | | ...

Core Viewpoint - The innovative drug concept stocks experienced a significant rally on October 31, with multiple stocks reaching their daily limit up or showing substantial gains, indicating a strong market sentiment towards the pharmaceutical sector [1]. Group 1: Stock Performance - Sangfor Health (三生国健) surged by 20% to a price of 72.96 [2] - Shuyou Shen (舒泰神) increased by 14.29% to 36.47 [2] - Tuo Jing Life (透景生命) rose by 11.97% to 24.78 [2] - Maiwei Biotechnology (迈威生物-U) gained 11.69% to 47.23 [2] - Zejing Pharmaceutical (泽璟制药-U) climbed 11.06% to 99.18 [2] - Rongchang Biopharmaceutical (荣昌生物) went up by 10.87% to 98.30 [2] - Other notable gainers included Haitai Biotechnology (海特生物) at +10.33% and Weiguan Biotechnology (微感生物) at +10.19% [2]. Group 2: Hong Kong Market Performance - Fosen Pharmaceutical (福森药业) saw a remarkable increase of 53.62% to 1.060 [3] - Yingtou Biotechnology (映图生物-B) rose by 12.44% to 318.200 [3] - Yaojie Jiankang (药捷家康-B) increased by 9.45% to 190.000 [3] - Other stocks such as Innovent Biologics (信达生物) and Jinfang Pharmaceutical (劲方医药) also experienced gains of 8.18% and 8.05% respectively [3].

Summary of Key Points Group 1: 52-Week Highs - A total of 45 stocks reached their 52-week highs as of October 23, with notable performers including Base Champion Group (08460) at 234.56%, Tianjin Chuangye Environmental Protection Co., Ltd. (01065) at 136.88%, and Liji Engineering Holdings (01690) at 80.26% [1] - The closing prices and peak prices for the top three stocks are as follows: Base Champion Group closed at 0.250 with a peak of 0.455, Tianjin Chuangye at 4.880 with a peak of 10.020, and Liji Engineering at 0.105 with a peak of 0.137 [1] Group 2: 52-Week Lows - The report also highlighted stocks that reached their 52-week lows, with Huaxi Holdings (01689) showing a decline of 16.67%, China New Economy Equity (02958) down by 14.17%, and Agile Holdings (00186) down by 13.16% [2] - The closing prices and lowest prices for the top three declining stocks are: Huaxi Holdings at 0.400 with a low of 0.350, China New Economy at 0.123 with a low of 0.103, and Agile Holdings at 0.165 with a low of 0.165 [2]

Core Viewpoint - Jinfang Pharmaceutical-B (02595.HK) experienced significant volatility in its stock price, initially dropping over 8% before recovering to a gain of over 9% near the market close [2]. Group 1 - The stock price of Jinfang Pharmaceutical-B reached 28.3 HKD, reflecting a 6.71% increase at the time of reporting [2]. - The trading volume for Jinfang Pharmaceutical-B was reported at 44.5183 million HKD [2].

Core Viewpoint - Jinfang Pharmaceutical-B (02595) experienced significant stock volatility, initially dropping over 8% before recovering to a gain of 6.71%, closing at 28.3 HKD with a trading volume of 44.5183 million HKD [1] Group 1: Clinical Development - Jinfang Pharmaceutical announced the initiation of an Ib/II phase study for its oral high-potency and high-selectivity small molecule KRAS G12D inhibitor GFH375, in combination therapy for treating KRAS G12D mutant advanced solid tumors, with the first patient enrolled at Peking University Cancer Hospital [1] - The study received clinical trial approval from the National Medical Products Administration in September 2023, involving combination therapies with cetuximab or chemotherapy, with GFH375 being part of the first-line treatment regimen for pancreatic ductal adenocarcinoma (PDAC) [1] Group 2: Research Presentation - Data on GFH375 as a monotherapy for KRAS G12D mutant PDAC patients was presented at the 2025 ESMO annual meeting, highlighting its efficacy and safety [1] - The oral presentation was conducted by Professor Zhou Aiping from the Chinese Academy of Medical Sciences Cancer Hospital, focusing on the study data from the 600 mg QD (RP2D) dose group of PDAC patients, demonstrating significant efficacy and manageable safety [1]